title: Infliximab does not interfere with insulin secretion, insulin resistance and production of GAD and islet cell antibodies in patients with Crohn's disease.
authors.affiliation: Department of Geriatrics and Metabolic Disease, Second University of Naples, Italy. sandro.gentile@unima2.it
authors.forename: S
authors.initials: S
authors.lastname: Gentile
authors.forename: G
authors.initials: G
authors.lastname: Guarino
authors.forename: A
authors.initials: A
authors.lastname: Bizzarro
authors.forename: A
authors.initials: A
authors.lastname: De Bellis
authors.forename: R
authors.initials: R
authors.lastname: Torella
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001323:Autoantibodies / Q000097:blood*; D003424:Crohn Disease / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D005968:Glutamate Decarboxylase / Q000097:blood; D006801:Humans; D000069285:Infliximab; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D007333:Insulin Resistance / Q000502:physiology*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000276:immunology; D008297:Male; D008875:Middle Aged
chemical_list: D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D005765:Gastrointestinal Agents; D007328:Insulin; C024211:islet cell antibody; D000069285:Infliximab; D005968:Glutamate Decarboxylase